eSight: the low vision device proven to enhance visual acuity¹
A clinically validated, FDA-registered low vision device designed to help your patients achieve up to 20/20 visual acuity¹
eSight: a proven low vision device for your patients with central vision loss¹
eSight enables patients with central vision loss to achieve up to 20/20 visual acuity.¹ It works by stimulating the synaptic nerve activity in the remaining photoreceptor function in the patient’s eyes to provide increased visual information to the brain. In doing so, eSight delivers life-changing results for thousands of people with macular degeneration, diabetic retinopathy, Stargardt disease and more.¹
eSight provides unprecedented improvement in a wide range of visual performance measures for patients with one of over 20 different eye conditions associated with central vision loss.¹ eSight is a class 1 medical device that is registered with the FDA and EUDAMED, and inspected by Health Canada.
Over 2/3 of eSight users reported sight enhancement when diagnosed with Macular Degeneration, Stargardt Disease, Diabetic Retinopathy, Aniridia, Uveitis, Optic Nerve Hypoplasia, Ocular Albinism, and Coloboma. ¹ *
*For a full list of diagnoses, please see the publication that is discussed in further detail below.
eSight Features
Capture
A small, high-speed, high-definiton camera captures everthing the wearer is looking at.
Project
Advanced, clinically validated algorithms optimize and enhance the footage.
Display
The footage is presented on two near-to-eye screens in real time with stunning clarity.
Control
The built-in trackpad allows for touch vision controls like zoom and contrast.
Do More
The wireless remote controller or mobile apps for even more advanced capabilities.
eSight is clinically validated through a peer-reviewed multicenter trial
A multisite, prospective, single-arm study that involved six recruitment centers investigated the short- and medium-term effects of eSight. With a sample size of n=51, this study primarily demonstrated¹:
- A seven-line gain in distance acuity
- 100% mobility retention
- 12 letter contrast improvement
- Improvement in critical print size and reading acuity
- Significant increase in facial recognition
Published in the Journal of Optometry and Vision Science. eQUEST, ClinicalTrials.gov Identifier NCT02616900.
eSight Eyewear Significantly Improves Distance Acuity
Figure 1. Distance acuity equivalent of print size correctly read on the ETDRS chart at baseline without the device, at fitting with the device, and after 3 months of device use. Mean baseline acuity without device was 20/177 (mean logMAR, 0.95 [SD, 0.25]), which improved to 20/32 (mean, 0.20 [SD, 0.31]) with the device but stayed unchanged after 3 months of device use and training (mean, 0.19 [SD, 0.30]). *Statistically significant differences. ETDRS = Early Treatment Diabetic Retinopathy Study.
eSight Eyewear Significantly Improves Reading Acuity
Figure 2. Reading acuity equivalent of print size read on the MNREAD chart at baseline without the device, at fitting with the device, and after 3 months of device use. Mean baseline reading acuity without device was 20/159 (mean logMAR, 0.90 [SD, 0.34]), which improved to 20/43 (mean, 0.33 [SD, 0.39]) with the device but stayed unchanged after 3 months of device use and training (mean, 0.24 [SD, 0.36]). *Statistically significant differences.
Our eQuest partners
eSight TeleHealth is a remote training program that allows referred patients to experience eSight
The eSight TeleHealth program is proven to significantly improve patient quality of life through multiple peer-reviewed randomized controlled trials (RCT).2,3
The feasibility RCT demonstrated2:
- High accessibility with 93% of patients accessing the platform
- Only 14% requiring assistance from friends or family
- Minor technical issues with no cause for withdrawal
- Global acceptability with 100% overall satisfaction reported
When exploring quality of life as the primary outcome, eSight TeleHealth intervention resulted in3:
- Significantly higher satisfaction at 3-months
- Immediate improvements in functional vision and visual ability scores which were maintained for 6-months
- Rare experiences of cybersickness or disorientation side effects
Change the lives of your low vision patients with the leading wearable device
Experience the ease of eSight TeleHealth
Refer your patients to eSight Telehealth, and eSight specialists will ensure eligibility through an in-home evaluation of the device via TeleHealth. With the support of the TeleHealth training programs, eSight is efficient, reduces travel time, and offers a seamless, patient-centered experience from referral to usage.3
The program includes:
- An appointment with an eSight clinical specialist who will train and guide patients on using the device
- The use of an eSight 4 device for several days for evaluation after the training session
- No cost or financial obligation
Visual impairment and its impacts beyond sight
Approximately 2.2 billion people are visually impaired globally, of which 217 million have significant visual impairment, and 36 million are blind.4,5
Impaired visual function is associated with reduced cognitive function6 which can impact7:
- Language
- Memory
- Attention
- Visuospatial Ability
Vision impairment is correlated with unintentional injuries, loneliness, and diminished quality of life, and it poses a greater risk for developing mood disorders such as depression.8-11 In one study, up to 45.2% of adults with severe visual impairment reported moderate-to-severe depressive symptoms.12
As vision acuity declines, patients are willing to trade a significantly higher percentage of their remaining lifetime to regain vision.13
Specifically, 67% and 51% of patients in one study (n=72) were willing to trade remaining life years, and willing to risk chance of death, respectively, for perfect vision in both eyes.13 This was not limited to the legally blind, as patients with 20/60 to 20/100 visual acuity were willing to trade 43% of their remaining life years.11
Low vision patients: case studies and user testimonials
From seeing the faces of loved ones and advancing in all levels of education and work, to resuming hobbies as diverse as cooking, gardening, golf, and travel, eSight dramatically improves the quality of life for visually impaired patients allowing them to do all the things that sighted people take for granted.
Discover how eSight’s vision-enhancing electronic glasses have changed the lives of thousands of patients with low vision or legal blindness.
Beautiful stories from real users
Download eSight resources to learn more about how the leading low vision device can help your patients
References
- Wittich, W., Lorenzini, M. C., Markowitz, S. N., Tolentino, M., Gartner, S. A., Goldstein, J. E., & Dagnelie, G. (2018). The Effect of a Head-mounted Low Vision Device on Visual Function. Optometry and vision science : official publication of the American Academy of Optometry, 95(9), 774–784. https://doi.org/10.1097/OPX.0000000000001262
- Lorenzini, M.-C., & Wittich, W. (2021). Head-mounted Visual Assistive Technology-related Quality of Life Changes after Telerehabilitation. Optometry and Vision Science: Official Publication of the American Academy of Optometry, 98(6), 582-591. https://doi.org/10.1097/OPX.0000000000001705
- Lorenzini, M.-C., & Wittich, W. (2021). Personalized Telerehabilitation for a Head-mounted Low Vision Aid: A Randomized Feasibility Study. Optometry and Vision Science: Official Publication of the American Academy of Optometry, 98(6), 570-581. https://doi.org/10.1097/OPX.0000000000001704
- World Report on Vision. World Health Organization; 2019.
- Bourne, R. R. A., et al. (2017). Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: A systematic review and meta-analysis. The Lancet. Global Health, 5(9), e888-e897. https://doi.org/10.1016/S2214-109X(17)30293-0
- Zheng, D. D., et al. (2018). Longitudinal Associations Between Visual Impairment and Cognitive Functioning: The Salisbury Eye Evaluation Study. JAMA Ophthalmology, 136(9), 989-995. https://doi.org/10.1001/jamaophthalmol.2018.2493
- Varadaraj, V., et al. (2021). Association of Vision Impairment With Cognitive Decline Across Multiple Domains in Older Adults. JAMA Network Open, 4(7), e2117416. https://doi.org/10.1001/jamanetworkopen.2021.17416
- Khorrami-Nejad, M., Sarabandi, A., Akbari, M. R., & Askarizadeh, F. (2016). The Impact of Visual Impairment on Quality of Life. Medical hypothesis, discovery & innovation ophthalmology journal, 5(3), 96–103.
- Dhital, A., et al. (2010). Visual loss and falls: A review. Eye (London, England), 24(9), 1437-1446. https://doi.org/10.1038/eye.2010.60
- Brunes, A., et al. (2019). Loneliness among adults with visual impairment: Prevalence, associated factors, and relationship to life satisfaction. Health and Quality of Life Outcomes, 17(1), 24. https://doi.org/10.1186/s12955-019-1096-y
- Nyman, S. R., et al. (2010). Psychosocial impact of visual impairment in working-age adults. The British Journal of Ophthalmology, 94(11), 1427-1431. https://doi.org/10.1136/bjo.2009.164814
- Demmin, D. L., & Silverstein, S. M. (2020). Visual Impairment and Mental Health: Unmet Needs and Treatment Options. Clinical Ophthalmology, 14, 4229-4251. https://doi.org/10.2147/OPTH.S258783
- Brown, G. C., et al. (2000). Utility values and age-related macular degeneration. Archives of Ophthalmology (Chicago, Ill.: 1960), 118(1), 47-51. https://doi.org/10.1001/archopht.118.1.47